Vanda (VNDA) Stock Skyrockets on FDA Approval for Bipolar, Schizophrenia Drug

Vanda Pharmaceuticals (NASDAQ: VNDA) is seeing a dramatic pre-market surge on February 23, 2026, climbing to $8.17, a gain of $2.41 or 41.84%, following the company’s announcement that the U.S. Food and Drug Administration has approved its new drug BYSANTI™ (milsaperidone) for the treatment of Bipolar I manic episodes and schizophrenia in adults.

The approval marks Vanda’s second FDA win in less than two months, coming on the heels of the December 2025 clearance of NEREUS™, and has reignited investor interest in the small-cap biopharmaceutical firm. With patent protection extending through 2044 and a commercial launch targeted for Q3 2026, the market is responding to what many see as a meaningful turning point in Vanda’s growth trajectory.

FDA Approval and What Makes BYSANTI™ Stand Out

BYSANTI™ is classified as a New Chemical Entity within the atypical antipsychotic drug class, a designation that carries significant commercial and regulatory weight, including robust patent protection. The drug rapidly interconverts to iloperidone, the active ingredient in Vanda’s existing product Fanapt®, providing dual active molecules that work by antagonizing dopamine D2, serotonin 5-HT2A, and alpha1-adrenergic receptors to modulate key pathways in these disorders.

This bioequivalence to iloperidone allowed BYSANTI™ to leverage over 100,000 patient-years of real-world safety data, enabling a notably streamlined path through the approval process. Its unique receptor binding profile, featuring strong alpha-adrenergic activity exceeding dopamine and serotonin binding, also opens the door for future investigation in conditions involving hostility, agitation, and hyperarousal, further broadening its commercial potential.

Join our Telegram group and never miss a breaking digital asset story.

VNDA Stock Brief: Pre-Market Surge and Key Metrics

VNDA is surging over 41% in pre-market trading on February 23, climbing to $8.17 from its previous close of $5.76, as investors pile into the stock following the FDA approval announcement. The pre-market move pushes the stock well above its recent trading range and toward its 52-week high of $9.60, with the company’s market capitalization sitting at approximately $340 million.

The stock’s year-to-date performance had been under significant pressure heading into the approval, down roughly 34.69% compared to the S&P 500’s modest gain of 0.94%, though the one-year return of 28.29% tells a more constructive story. Analyst price targets range from $7.50 to $22.00, with an average target of $13.62, well above even today’s pre-market levels, and HC Wainwright & Co. recently raised its target to $22 while maintaining a Buy rating.

With BYSANTI™ also being evaluated as an adjunctive treatment for treatment-resistant major depressive disorder, with trial results expected by end of 2026, the stock’s re-rating thesis is gaining meaningful traction among investors tracking the company’s pipeline momentum.

Disclaimer: The author does not hold or have a position in any securities discussed in the article. All stock prices were quoted at the time of writing.